MRD testing using a ctDNA to Predict Recurrence of Metastatic Colorectal Cancer

Arndt Vogel shared on X:

“MRD testing using a ctDNA to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.

52 patients, 230 samples, 69.2% of patients with recurrence. Only ctDNA demonstrate statistical association with recurrence. More data to support MRD testing in CRC.”

Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment

Autors: Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, Joy X. Jarnagin, Victoria M. Raymond, Carlos U. Corvera, Kenzo Hirose, Eric K. Nakakura, Ryan B. Corcoran, Katherine Van Loon, Chloe E. Atreya

Source: Arndt Vogel/X

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.